www.klinickafarmakologie.cz / Klin Farmakol Farm 2022;36(4):150-155 / KLINICKÁ FARMAKOLOGIE A FARMACIE 155 PŘEHLEDOVÉ ČLÁNKY Opětovné nasazení klozapinu 29. West S, Rowbotham D, Xiong G, Kenedi C. Clozapine induced gastrointestinal hypomotility: A potentially life threatening adverse event. A review of the literature. General Hospital Psychiatry. 2017;46:32-37. 30. Every-Palmer S, McLean RM, Ellis PM, Harrison-Woolrych M. Life-threatening clozapine-induced gastrointestinal hypomotility: An analysis of 102 cases. The Journal of Clinical Psychiatry. 2008;69(5):759-768. 31. Richardson N, Greenway SC, Bousman CA. Clozapine- -induced myocarditis and patient outcomes after drug rechallenge following myocarditis: A systematic case review. Psychiatry Research. 2021;305. 32. Masopust J, Kopeček M, Protopopová D. Sledování tělesného zdraví u pacientů se závažnými neorganickými duševními poruchami (psychózy, bipolární porucha, depresivní porucha). Doporučené postupy psychiatrické péče Psychiatrické společnosti ČLS JEP. 2020. https://postupy-pece.psychiatrie.cz/obecna-psychiatrie/sledovani-telesneho-zdravi 33. Ronaldson KJ, Fitzgerald PB, Taylor AJ et al: A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75 cases and 94 controls. Australian & New Zealand Psychiatry. 2011; 45(6): 458–65. 34. Bellissima BL, Tingle MD, Cicović A et al: A systematic review of clozapine induced myocarditis. International Journal of Cardiology. 2018; 259: 122–29. 35. Vickers M, Ramineni V, Malacova E, et al. Risk factors for clozapine-induced myocarditis and cardiomyopathy: A systematic review and meta-analysis. Acta Psychiatrica Scandinavica. 2022;145(5):442-455. 36. Hosseini SA, Skrzypcak B, Yasaei R, et al. Successful Clozapine Re-Challenge After Suspected Clozapine-Induced Myocarditis. American Journal of Case Reports. 2020;21:1-6. 37. Noël M-C, Powell V, Burton L et al: Clozapine-related myocarditis and rechallenge: A case series and clinical review. Journal of Clinical Psychopharmacology. 2019; 39(4): 380–85 38. Ronaldson KJ, Fitzgerald PB, Taylor AJ et al: Rapid clozapine dose titration and concomitant sodium valproate increase the risk of myocarditis with clozapine: A case-control study. Schizophrenia Research. 2012; 141(2–3): 173–78. 39. de Leon J, Tang Y-L, Baptista T, et al. Titrating clozapine amidst recommendations proposing high myocarditis risk and rapid titrations. Acta Psychiatrica Scandinavica. 2015;132(4):242-243. 40. Griffin JM, Woznica E, Gilotra NA, Nucifora FC Jr. Clozapine-Associated Myocarditis: A Protocol for Monitoring Upon Clozapine Initiation and Recommendations for How to Conduct a Clozapine Rechallenge. Journal of Clinical Psychopharmacology. 2021;41(2):180-185. 41. Hiemke C, Bergemann N, Clement HW, et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry. 2018;51(1-02):e1. 42. Hefner G, Shams M, Unterecker S, Falter T, Hiemke C. Inflammation and psychotropic drugs: the relationship between C-reactive protein and antipsychotic drug levels. Psychopharmacology. 2016;233(9):1695-1705. 43. Whiskey E, Taylor D. Restarting clozapine after neutropenia : Evaluating the possibilities and practicalities. CNS drugs. 2007;21(1):25-35. 44. Malik S, Lally J, Ajnakina O, et al. Sodium valproate and clozapine induced neutropenia: A case control study using register data. Schizophrenia Research. 2018;195:267-273. 45. Myles N, Myles H, Clark SR, et al. Use of granulocyte-colony stimulating factor to prevent recurrent clozapine-induced neutropenia on drug rechallenge: A systematic review of the literature and clinical recommendations. Australian and New Zealand Journal of Psychiatry. 2017;51(10):980-989. 46. Lally J, Malik S, Krivoy A, Whiskey E, Taylor DM, Gaughran FP, Flanagan RJ, Mijovic A, MacCabe JH. The Use of Granulocyte Colony-Stimulating Factor in Clozapine Rechallenge: A Systematic Review. Journal of Clinical Psychopharmacology. 2017;37(5):600-604. 47. Lichnovský O, Ustohal L. Vysazení klozapinu z důvodu neutropenie a možnosti jeho opětovného nasazení do medikace. Psychiatrie. 2022;4:167-171. 48. Yadav D, Burton S, Sehgal C. Clozapine-induced neutropenia reversed by lithium. Progress in Neurology & Psychiatry. 2016;20(3):13-15. 49. Kanaan RA, Kerwin RW. Lithium and clozapine rechallenge: a retrospective case analysis. The Journal of Clinical Psychiatry. 2006;67(5):756-760. 50. Kourti, K. Paschalidis, C-M. Platsa, et al. Clozapine Rechallenge with Lithium After Double Induced Neutropenia: A Case Report. Dialogues in Clinical Neuroscience & Mental Health. 2019;1(4):150-157. 51. Carmen J, Okafor K, Ike E. The effects of lithium therapy on leukocytes: a 1-year follow-up study. Journal of the National Medical Association. 1993;85(4):301-303. 52. Clozapine treatment guidelines https://www.candi.nhs. uk/sites/default/files/Clozapine%20Treatment%20guidelines%20_PHA06_August%202021.pdf 53. Boazak M, Goldsmith DR, Cotes RO. Mask Off? Lithium Augmentation for Clozapine Rechallenge After Neutropenia or Agranulocytosis: Discontinuation Might Be Risky. The Primary Care Companion for CNS disorders. 2018;20(6). 54. Béchard L, Morasse-Bégis M, Corbeil O, et al. Clozapine Rechallenge or Continuation Despite Neutropenia, an Extended Follow-up of a Consecutive Quebec Case Series. Journal of Clinical Psychopharmacology. May 2022. 55. Dunk LR, Annan LJ, Andrews CD. Rechallenge with clozapine following leucopenia or neutropenia during previous therapy. The British Journal of Psychiatry : the journal of mental science. 2006;188:255-263. 56. Shuman M, Dilich A, Moss L. Never Say Never: Successful Clozapine Rechallenge After Multiple Episodes of Neutropenia. FOCUS. 2021;19:66-70. 57.Oloyede E, Blackman G, Whiskey E, et al. Clozapine haematological monitoring for neutropenia: a global perspective. Epidemiology and Psychiatric Sciences. 2022;31:e83.
RkJQdWJsaXNoZXIy NDA4Mjc=